These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 29685206)
41. Lesion probability mapping to explain clinical deficits and cognitive performance in multiple sclerosis. Kincses ZT; Ropele S; Jenkinson M; Khalil M; Petrovic K; Loitfelder M; Langkammer C; Aspeck E; Wallner-Blazek M; Fuchs S; Jehna M; Schmidt R; Vécsei L; Fazekas F; Enzinger C Mult Scler; 2011 Jun; 17(6):681-9. PubMed ID: 21177325 [TBL] [Abstract][Full Text] [Related]
42. The changing clinical course of multiple sclerosis: a matter of gray matter. Calabrese M; Romualdi C; Poretto V; Favaretto A; Morra A; Rinaldi F; Perini P; Gallo P Ann Neurol; 2013 Jul; 74(1):76-83. PubMed ID: 23494723 [TBL] [Abstract][Full Text] [Related]
43. Association of cerebrospinal fluid levels of lateral olfactory tract usher substance (LOTUS) with disease activity in multiple sclerosis. Takahashi K; Kurihara Y; Suzuki Y; Goshima Y; Tanaka F; Takei K JAMA Neurol; 2015 Feb; 72(2):176-9. PubMed ID: 25437093 [TBL] [Abstract][Full Text] [Related]
44. Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis. Tauhid S; Chu R; Sasane R; Glanz BI; Neema M; Miller JR; Kim G; Signorovitch JE; Healy BC; Chitnis T; Weiner HL; Bakshi R J Neurol; 2015 Nov; 262(11):2425-32. PubMed ID: 26205635 [TBL] [Abstract][Full Text] [Related]
45. The immunology of multiple sclerosis: disease mechanisms and therapeutic targets. Holmøy T Minerva Med; 2008 Apr; 99(2):119-40. PubMed ID: 18431322 [TBL] [Abstract][Full Text] [Related]
46. Polyarteritis nodosa with central nervous system involvement mimicking relapsing-remitting multiple sclerosis. Ueno K; Matsushima A; Hineno A; Fukushima K; Tazawa K; Matsuda M; Ikeda S Mod Rheumatol; 2014 May; 24(3):525-8. PubMed ID: 24506572 [TBL] [Abstract][Full Text] [Related]
47. Complement Receptor 2 is increased in cerebrospinal fluid of multiple sclerosis patients and regulates C3 function. Lindblom RP; Aeinehband S; Ström M; Al Nimer F; Sandholm K; Khademi M; Nilsson B; Piehl F; Ekdahl KN Clin Immunol; 2016 May; 166-167():89-95. PubMed ID: 27085202 [TBL] [Abstract][Full Text] [Related]
48. Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. Alexander JS; Chervenak R; Weinstock-Guttman B; Tsunoda I; Ramanathan M; Martinez N; Omura S; Sato F; Chaitanya GV; Minagar A; McGee J; Jennings MH; Monceaux C; Becker F; Cvek U; Trutschl M; Zivadinov R J Neurol Sci; 2015 Aug; 355(1-2):84-9. PubMed ID: 26073484 [TBL] [Abstract][Full Text] [Related]
49. Regional hippocampal atrophy in multiple sclerosis. Sicotte NL; Kern KC; Giesser BS; Arshanapalli A; Schultz A; Montag M; Wang H; Bookheimer SY Brain; 2008 Apr; 131(Pt 4):1134-41. PubMed ID: 18375977 [TBL] [Abstract][Full Text] [Related]
50. Histo-clinical variation in multiple sclerosis: Heterogeneous proteolytic immunogenic processing. Westall FC Med Hypotheses; 2006; 66(3):566-9. PubMed ID: 16236458 [TBL] [Abstract][Full Text] [Related]
51. Relapsing demyelinating disease affecting both the central and peripheral nervous systems. Zéphir H; Stojkovic T; Latour P; Lacour A; de Seze J; Outteryck O; Maurage CA; Monpeurt C; Chatelet P; Ovelacq E; Vermersch P J Neurol Neurosurg Psychiatry; 2008 Sep; 79(9):1032-9. PubMed ID: 18208860 [TBL] [Abstract][Full Text] [Related]
52. Seasonal variations in exacerbations and MRI parameters in relapsing-remitting multiple sclerosis. Koziol JA; Feng AC Neuroepidemiology; 2004; 23(5):217-23. PubMed ID: 15316247 [TBL] [Abstract][Full Text] [Related]
53. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS. Zivadinov R; Munschauer FE; Ramanathan M; Benedict RH; Weinstock-Guttman B Drugs Today (Barc); 2008 Aug; 44(8):601-13. PubMed ID: 18846271 [TBL] [Abstract][Full Text] [Related]
54. Characterization of brain lesions in a mouse model of progressive multiple sclerosis. Levy H; Assaf Y; Frenkel D Exp Neurol; 2010 Nov; 226(1):148-58. PubMed ID: 20736006 [TBL] [Abstract][Full Text] [Related]
55. Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. De Stefano N; Giorgio A; Battaglini M; Rovaris M; Sormani MP; Barkhof F; Korteweg T; Enzinger C; Fazekas F; Calabrese M; Dinacci D; Tedeschi G; Gass A; Montalban X; Rovira A; Thompson A; Comi G; Miller DH; Filippi M Neurology; 2010 Jun; 74(23):1868-76. PubMed ID: 20530323 [TBL] [Abstract][Full Text] [Related]
56. Similar pro- and anti-inflammatory cytokine production in the different clinical forms of multiple sclerosis. Durán I; Martínez-Cáceres EM; Brieva L; Tintoré M; Montalban X Mult Scler; 2001 Jun; 7(3):151-6. PubMed ID: 11475437 [TBL] [Abstract][Full Text] [Related]